Cime Therapeutics
Denver, US · Founded 2024 · Delaware corporation · 3 known investors
Cime Therapeutics is developing a chemistry-first drug discovery platform that combines automation, AI/ML, and synthetic chemistry to make molecules faster and more cost-effectively. The platform integrates the synthesis and screening stages to accelerate the Design-Make-Test-Analyze cycle in pharmaceutical discovery.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
JB
James BrewsterChief Executive Officer
JT
James Thomas Brewster IINamed on SEC filing
PB
Patrick BarbourAssociate Director
GT
Gregory ThiabaudAssociate Director
Board
CE
Investors · 3
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 1 round · 2025
▶$2.1MraisedMar 2025 · 3 investors · BiotechnologyRule 506(b)
▶$2.1MraisedMar 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James Thomas Brewster IIExecutive Officer, Director
- Chris EricksonDirector
- Offering amount
- $2.5M
- Amount sold
- $2.1M
- Proceeds to insiders
- $80K
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Cime Therapeutics do?
- Cime Therapeutics is developing a chemistry-first drug discovery platform that combines automation, AI/ML, and synthetic chemistry to make molecules faster and more cost-effectively. The platform integrates the synthesis and screening stages to accelerate the Design-Make-Test-Analyze cycle in pharmaceutical discovery.
- Who are Cime Therapeutics's investors?
- Cime Therapeutics's investors include DYDX Capital, Service Provider Capital, Range VC.
- How much funding has Cime Therapeutics raised?
- Cime Therapeutics has disclosed $2.1M raised across 1 round.
- Where is Cime Therapeutics headquartered?
- Cime Therapeutics is headquartered in Denver, US.